Cartesian Therapeutics, Inc. (NASDAQ: RNAC) is a clinical-stage biotechnology company pioneering messenger RNA (mRNA) cell therapies for the treatment of autoimmune diseases. The company's portfolio is led by Descartes-08, an autologous anti-BCMA mRNA CAR-T, being developed for Myasthenia Gravis and other autoimmune indications. Cartesian aims to broaden the reach of cell therapy to autoimmune diseases by engineering therapies that are purposefully designed to be administered out-patient without lymphodepleting chemotherapy.
The Gaithersburg headquarters serves as the primary center for Cartesian's executive leadership, research and development operations, clinical development, and corporate administrative functions.
The facility is situated in a modern biotechnology park, likely equipped with advanced laboratory spaces for cell therapy research, process development, and analytics. It also includes manufacturing capabilities.
Cartesian fosters a science-driven, innovative, and collaborative work environment. The culture emphasizes scientific excellence, patient focus, and a commitment to developing transformative therapies for autoimmune diseases.
Its location in the Maryland biotech corridor provides strategic access to a rich talent pool, leading research institutions, and proximity to regulatory agencies such as the U.S. Food and Drug Administration (FDA).
Cartesian Therapeutics's operations, including research, development, and clinical trials, are primarily centered in the United States. While its therapeutic candidates, if approved, could address global patient populations, the company's current physical and operational footprint is U.S.-based. Future global expansion may occur through partnerships for clinical trials or commercialization.
22275 Global Drive
Gaithersburg
Maryland
USA
Address: Previously leased manufacturing facility in Frederick, MD
It formerly supported the company's development pipeline by providing dedicated space for specialized cell therapy manufacturing. Cartesian Therapeutics has been evaluating its future manufacturing strategy, which may include extending the lease, securing new facilities, or using contract manufacturers.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Cartesian' leadership includes:
Cartesian has been backed by several prominent investors over the years, including:
The past 12 months featured significant executive changes primarily due to the merger of Selecta Biosciences and Cartesian Therapeutics in November 2023. This led to the formation of a new leadership team for the combined entity, Cartesian Therapeutics, including a new CEO, CFO, COO, CMO, and CSO, and departures from the former Selecta Biosciences leadership.
Discover the tools Cartesian uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Cartesian Therapeutics likely utilizes a standard corporate email format, typically combining an employee's first initial and last name, or full name, with the company domain. This is a common practice for professional communication.
[first_initial][last_name]@cartesiantherapeutics.com
Format
mkalayoglu@cartesiantherapeutics.com
Example
80%
Success rate
GlobeNewswire • March 28, 2024
Cartesian Therapeutics announced its financial results for the fiscal year ended December 31, 2023, and provided corporate updates, including progress on its lead clinical program, Descartes-08 for Myasthenia Gravis....more
GlobeNewswire • January 4, 2024
The company reported positive initial data from its Phase 2b study of Descartes-08 in patients with generalized Myasthenia Gravis, indicating potential for clinically meaningful improvement and a favorable safety profile....more
GlobeNewswire • November 14, 2023
Selecta Biosciences and Cartesian Therapeutics announced the successful completion of their merger. The combined company now operates as Cartesian Therapeutics, Inc., trading on Nasdaq under 'RNAC', and is focused on advancing Cartesian's portfolio of RNA cell therapies....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Cartesian, are just a search away.